<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231104059958N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-19</date_registration>
      <primary_sponsor>Faculty of Veterinary Medicine, Shiraz University</primary_sponsor>
      <public_title>The effect of consuming the prepared cakes with acorn flour in patients with metabolic syndrome</public_title>
      <acronym></acronym>
      <scientific_title>Comparison of the effect of consuming the prepared cakes with acorn flour and wheat flour following a hypocaloric diet on serum levels of adiponectin, inflammatory factors and oxidative stress parameters in obese and overweight patients with metabolic syndrome: a double-blind clinical trial</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2022-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73597</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Triple blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: After the 2-week run-in period, the patients will be randomly allocated to the intervention or placebo (control) group using the balanced block randomization method with a block size of 4. The treatment allocation will performed using software-generated random numbers. Patients in the intervention group will consume two daily servings (2×30 g) of AC (n= 33) as snacks for 8 weeks a day; while those in the control group will be assigned to equal amounts of PC (n= 33) for the same period. The cakes will be prepared in the city of Shiraz. The intervention and control cakes will be equal in terms of shape, size, color, and taste. Also, both cakes will be prepared with identical packages and labeled as A or B, so that both study personnel and participants are unaware of the type of treatment, Blinding description: Study participants, researchers, and laboratory personnel are blinded to group allocation until after the study. The designed placebo is completely similar to the intervention group in terms of color, smell, size and model. In order to blind the researcher, help is taken from a person who is not involved in the research process. The set of packs containing cakes prepared by a third party are coded as A and B.</study_design>
      <phase>3</phase>
      <hc_freetext>Condition 1: Metabolic syndrome. Condition 2: Obesity due to excess calories.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: the group that received the super-beneficial cake containing oak powder. The amount of calories in both oak and wheat cakes will be equal, so due to the higher calorie content of oak flour, 10 grams of sweetened oak flour should be used in preparing a cake containing oak flour, and 13.8 grams of wheat flour should be used in preparing a cake containing wheat flour. will be. Other ingredients of both cakes will be similar. A cake with an approximate weight of 30 grams will be produced and packaged in a standard way and will be considered as part of a snack to be consumed once a day by the patient. Intervention 2: Control group: The group receiving a cake containing wheat flour, a cake with an approximate weight of 30 grams will be produced and packaged in a standard way and will be considered as a part of the patient's snack to be consumed once a day.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Laboratory data can be published

When:
After studying

To whom:
For researchers and people working in industry

Conditions:
Use of data in industry is allowed

Where to obtain:
Hamed Sadeghi-dehsahraei - via email
sadeghidehsahraiihamed@yahoo.com

How to obtain:
The possibility of applying by email will be checked and answered within two weeks

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>hamed sadeghi-dehsahraei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Islamic Republic Blvd</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>71946-84334</zip>
        <telephone>+98 71 3613 8618</telephone>
        <email>sadeghidehsahraiihamed@yahoo.com</email>
        <affiliation>Faculty of Veterinary Medicine, Shiraz University</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>hamed sadeghi-dehsahraei</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Islamic Republic Blvd</address>
        <city>shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>71946-84334</zip>
        <telephone>+98 71 3613 8618</telephone>
        <email>sadeghidehsahraiihamed@yahoo.com</email>
        <affiliation>Faculty of Veterinary Medicine, Shiraz University</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with metabolic syndrome
Waist circumference greater than 102 cm in men and 88 cm in women
Triglycerides equal to or greater than 150 mg/dL
HDL less than or equal to 40 in men and less than or equal to 50 in women
Blood pressure more than 130 to 85 mm Hg and blood sugar equal to or more than 100 mg/dL
Stable body weight (weight change less than 3 kg in the last 3 months)
Not participating in weight loss programs in the last 6 months</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>60 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Diabetic patients receiving blood sugar lowering drugs and insulin
History of alcohol consumption
Smoking
Pregnant and lactating women
People with mental illnesses, cancer, thyroid, cardiovascular, lung, kidney, liver, eating disorders
Taking drugs that affect appetite, body weight, calcium and vitamin D metabolism, and lipid metabolism or have an anti-inflammatory effect.
Taking antioxidants or multivitamins and any type of food supplement
Having lactose intolerance</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>E88.81</hc_code>
      <hc_code>E66.0</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Metabolic syndrome</hc_keyword>
      <hc_keyword>Obesity due to excess calories</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: the group that received the super-beneficial cake containing oak powder. The amount of calories in both oak and wheat cakes will be equal, so due to the higher calorie content of oak flour, 10 grams of sweetened oak flour should be used in preparing a cake containing oak flour, and 13.8 grams of wheat flour should be used in preparing a cake containing wheat flour. will be. Other ingredients of both cakes will be similar. A cake with an approximate weight of 30 grams will be produced and packaged in a standard way and will be considered as part of a snack to be consumed once a day by the patient.</i_keyword>
      <i_keyword>Control group: The group receiving a cake containing wheat flour, a cake with an approximate weight of 30 grams will be produced and packaged in a standard way and will be considered as a part of the patient's snack to be consumed once a day.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Interleukin-6. Timepoint: Before and after the intervention. Method of measurement: ELISA (Enzyme-Linked Immunosorbent Assay ) kit.</prim_outcome>
      <prim_outcome>C reactive protein. Timepoint: Before and after the intervention. Method of measurement: ELISA (Enzyme-Linked Immunosorbent Assay ) kit.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Malondialdehyde. Timepoint: before and after the intervention. Method of measurement: Thiobarbituric acid method.</sec_outcome>
      <sec_outcome>Total antioxidant capacity. Timepoint: before and after the intervention. Method of measurement: ElISA (Enzyme-linked immunosorbent assay) kit.</sec_outcome>
      <sec_outcome>Adiponectin. Timepoint: before and after the intervention. Method of measurement: ElISA (Enzyme-linked immunosorbent assay) kit.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name>Shiraz University of Medical Sciences</sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Faculty of Veterinary Medicine, Shiraz University</source_name>
      <source_name>Shiraz university of medical sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-10-14</approval_date>
        <contact_name>Ethics Committee of Shiraz University</contact_name>
        <contact_address>Eram Blvd shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
